GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.
| 
                                                                Synonyms: GA-101 | GA101 | Gazyva®
                                 obinutuzumab is an approved drug (FDA (2013), EMA (2014)) Compound class: 
                                                            Antibody
                                 
                                    
                                        Comment: Obinutuzumab is a third-generation, humanized and glyco-engineered anti-CD20 IgG1 mAb. Prior to 2009 obinutuzumab was known as afutuzumab. Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record.   View more information in the IUPHAR Pharmacology Education Project: obinutuzumab | 
| Classification  | |
| Compound class | Antibody | 
| Approved drug? | Yes. EU EMA (2014) | US FDA (2013) | 
| International Nonproprietary Names  | |
| INN number | INN | 
| 9043 | obinutuzumab | 
| Synonyms  | 
| GA-101 | GA101 | Gazyva® | 
| Database Links  | |
| Specialist databases | |
| IMGT/mAb-DB | 238 | 
| Other databases | |
| GtoPdb PubChem SID | 178103523 | 
| PubChem SID | 178103523 | 
| Search PubMed clinical trials | obinutuzumab | 
| Search PubMed titles | obinutuzumab | 
| Search PubMed titles/abstracts | obinutuzumab | 
| Wikipedia | Obinutuzumab |